Alternative screening approaches for discovery of Middle East respiratory syndrome coronavirus inhibitors.
Identifieur interne : 001707 ( Main/Exploration ); précédent : 001706; suivant : 001708Alternative screening approaches for discovery of Middle East respiratory syndrome coronavirus inhibitors.
Auteurs : Robert L. Lafemina [Oman]Source :
- Antimicrobial agents and chemotherapy [ 1098-6596 ] ; 2014.
Descripteurs français
- KwdFr :
- Antiviraux (pharmacologie), Bibliothèques de petites molécules (pharmacologie), Coronavirus du syndrome respiratoire du Moyen-Orient (), Coronavirus du syndrome respiratoire du Moyen-Orient (pathogénicité), Coronavirus du syndrome respiratoire du Moyen-Orient (physiologie), Humains, Lignée cellulaire, Repositionnement des médicaments, Tests de criblage à haut débit, Virus du SRAS (), Virus du SRAS (pathogénicité), Virus du SRAS (physiologie).
- MESH :
- pathogénicité : Coronavirus du syndrome respiratoire du Moyen-Orient, Virus du SRAS.
- pharmacologie : Antiviraux, Bibliothèques de petites molécules.
- physiologie : Coronavirus du syndrome respiratoire du Moyen-Orient, Virus du SRAS.
- Coronavirus du syndrome respiratoire du Moyen-Orient, Humains, Lignée cellulaire, Repositionnement des médicaments, Tests de criblage à haut débit, Virus du SRAS.
English descriptors
- KwdEn :
- Antiviral Agents (pharmacology), Cell Line, Drug Repositioning, High-Throughput Screening Assays, Humans, Middle East Respiratory Syndrome Coronavirus (drug effects), Middle East Respiratory Syndrome Coronavirus (pathogenicity), Middle East Respiratory Syndrome Coronavirus (physiology), SARS Virus (drug effects), SARS Virus (pathogenicity), SARS Virus (physiology), Small Molecule Libraries (pharmacology).
- MESH :
- chemical , pharmacology : Antiviral Agents, Small Molecule Libraries.
- drug effects : Middle East Respiratory Syndrome Coronavirus, SARS Virus.
- pathogenicity : Middle East Respiratory Syndrome Coronavirus, SARS Virus.
- physiology : Middle East Respiratory Syndrome Coronavirus, SARS Virus.
- Cell Line, Drug Repositioning, High-Throughput Screening Assays, Humans.
Abstract
Two coronaviruses causing severe respiratory disease and high mortality rates emerging within the past dozen years reinforces the need for clinically efficacious antivirals targeting coronaviruses. Alternative screening approaches for antivirals against the recently emergent Middle East respiratory syndrome coronavirus (MERS-CoV) may provide lead compounds to address this need. Two Antimicrobial Agents and Chemotherapy (AAC) papers screened libraries of approved compounds that may potentially be repurposed as MERS-CoV antivirals. A third AAC paper showed that a previously described severe acute respiratory syndrome coronavirus (SARS-CoV) helicase inhibitor also has activity against MERS-CoV.
DOI: 10.1128/AAC.03406-14
PubMed: 24867994
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000F88
- to stream PubMed, to step Curation: 000F88
- to stream PubMed, to step Checkpoint: 001048
- to stream Ncbi, to step Merge: 002896
- to stream Ncbi, to step Curation: 002896
- to stream Ncbi, to step Checkpoint: 002896
- to stream Main, to step Merge: 001713
- to stream Main, to step Curation: 001707
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Alternative screening approaches for discovery of Middle East respiratory syndrome coronavirus inhibitors.</title><author><name sortKey="Lafemina, Robert L" sort="Lafemina, Robert L" uniqKey="Lafemina R" first="Robert L" last="Lafemina">Robert L. Lafemina</name><affiliation wicri:level="1"><nlm:affiliation>Editor, Antimicrobial Agents and Chemotherapy, Schwenksville, Pennsylvania, USA robert.lafemina@gmail.com.</nlm:affiliation><country wicri:rule="url">Oman</country><wicri:regionArea>Editor, Antimicrobial Agents and Chemotherapy, Schwenksville, Pennsylvania</wicri:regionArea><wicri:noRegion>Pennsylvania</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24867994</idno><idno type="pmid">24867994</idno><idno type="doi">10.1128/AAC.03406-14</idno><idno type="wicri:Area/PubMed/Corpus">000F88</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F88</idno><idno type="wicri:Area/PubMed/Curation">000F88</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F88</idno><idno type="wicri:Area/PubMed/Checkpoint">001048</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001048</idno><idno type="wicri:Area/Ncbi/Merge">002896</idno><idno type="wicri:Area/Ncbi/Curation">002896</idno><idno type="wicri:Area/Ncbi/Checkpoint">002896</idno><idno type="wicri:Area/Main/Merge">001713</idno><idno type="wicri:Area/Main/Curation">001707</idno><idno type="wicri:Area/Main/Exploration">001707</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Alternative screening approaches for discovery of Middle East respiratory syndrome coronavirus inhibitors.</title><author><name sortKey="Lafemina, Robert L" sort="Lafemina, Robert L" uniqKey="Lafemina R" first="Robert L" last="Lafemina">Robert L. Lafemina</name><affiliation wicri:level="1"><nlm:affiliation>Editor, Antimicrobial Agents and Chemotherapy, Schwenksville, Pennsylvania, USA robert.lafemina@gmail.com.</nlm:affiliation><country wicri:rule="url">Oman</country><wicri:regionArea>Editor, Antimicrobial Agents and Chemotherapy, Schwenksville, Pennsylvania</wicri:regionArea><wicri:noRegion>Pennsylvania</wicri:noRegion></affiliation></author></analytic><series><title level="j">Antimicrobial agents and chemotherapy</title><idno type="eISSN">1098-6596</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (pharmacology)</term><term>Cell Line</term><term>Drug Repositioning</term><term>High-Throughput Screening Assays</term><term>Humans</term><term>Middle East Respiratory Syndrome Coronavirus (drug effects)</term><term>Middle East Respiratory Syndrome Coronavirus (pathogenicity)</term><term>Middle East Respiratory Syndrome Coronavirus (physiology)</term><term>SARS Virus (drug effects)</term><term>SARS Virus (pathogenicity)</term><term>SARS Virus (physiology)</term><term>Small Molecule Libraries (pharmacology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (pharmacologie)</term><term>Bibliothèques de petites molécules (pharmacologie)</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient ()</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient (pathogénicité)</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient (physiologie)</term><term>Humains</term><term>Lignée cellulaire</term><term>Repositionnement des médicaments</term><term>Tests de criblage à haut débit</term><term>Virus du SRAS ()</term><term>Virus du SRAS (pathogénicité)</term><term>Virus du SRAS (physiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Small Molecule Libraries</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term><term>Bibliothèques de petites molécules</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term><term>SARS Virus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cell Line</term><term>Drug Repositioning</term><term>High-Throughput Screening Assays</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term><term>Humains</term><term>Lignée cellulaire</term><term>Repositionnement des médicaments</term><term>Tests de criblage à haut débit</term><term>Virus du SRAS</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Two coronaviruses causing severe respiratory disease and high mortality rates emerging within the past dozen years reinforces the need for clinically efficacious antivirals targeting coronaviruses. Alternative screening approaches for antivirals against the recently emergent Middle East respiratory syndrome coronavirus (MERS-CoV) may provide lead compounds to address this need. Two Antimicrobial Agents and Chemotherapy (AAC) papers screened libraries of approved compounds that may potentially be repurposed as MERS-CoV antivirals. A third AAC paper showed that a previously described severe acute respiratory syndrome coronavirus (SARS-CoV) helicase inhibitor also has activity against MERS-CoV. </div></front></TEI><affiliations><list><country><li>Oman</li></country></list><tree><country name="Oman"><noRegion><name sortKey="Lafemina, Robert L" sort="Lafemina, Robert L" uniqKey="Lafemina R" first="Robert L" last="Lafemina">Robert L. Lafemina</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001707 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001707 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24867994
|texte= Alternative screening approaches for discovery of Middle East respiratory syndrome coronavirus inhibitors.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24867994" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |